Santosh Revankar
Overview
Explore the profile of Santosh Revankar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
13
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jadhav U, Solanki D, Kumar S, Hazra P, Alexander T, Gupta A, et al.
Cureus
. 2024 Dec;
16(11):e74115.
PMID: 39712757
Introduction: To understand the current clinical practices followed by healthcare professionals (HCPs) among populations with hypertension and obesity with sympathetic overactivity and develop strategies to improve the management of hypertension....
2.
Shaikh S, Vaidya V, Gupta A, Kulkarni R, Joshi A, Kulkarni M, et al.
Cureus
. 2024 Jun;
16(5):e59850.
PMID: 38854289
Management of type 2 diabetes mellitus (T2DM) largely relies on medication adherence of individuals with diabetes to achieve optimal glycemic control. The economic burden of diabetes could impede adherence, leading...
3.
Panneerselvam P, Biswas D, Singh H, Kumar K, Ravi Kumar P, Kalra P, et al.
Cureus
. 2023 Nov;
15(10):e47190.
PMID: 38021574
Background And Objective: The therapeutic use of vildagliptin and insulin (VIL-INS) or vildagliptin and metformin in combination with insulin (VIL-MET-INS) in the Indian scenario has yet to be explored by...
4.
Erande S, Mukhopadhyay J, Dange A, Deogaonkar A, Birla A, Doshi C, et al.
Cureus
. 2023 Oct;
15(9):e44548.
PMID: 37795066
Background Type 2 diabetes mellitus (T2DM) arises due to a range of pathological abnormalities, necessitating a combination therapy to achieve optimal glycemic control. Vildagliptin, an effective and selective DPP-4 inhibitor,...
5.
Mehta A, Jain P, Patil R, Sashi Kant T, Indurkar S, Kota S, et al.
Cureus
. 2022 Dec;
14(11):e31468.
PMID: 36523717
Background Rosuvastatin effectively reduces endogenous cholesterol synthesis and low-density lipoprotein (LDL) cholesterol and increases high-density lipoprotein (HDL) cholesterol. This study aimed to evaluate the clinical characteristics of patients and treatment...
6.
Vyas L, Pai Raiturker A, Sud S, Goyyal P, Abhyankar M, Revankar S, et al.
Bioinformation
. 2022 Nov;
18(2):103-110.
PMID: 36420435
Myo-Inositol and D-chiro-inositol (MI-DCI) are used in the treatment of polycystic Ovary syndrome (PCOS) due to their insulin-sensitizing actions. Therefore, it is of interest to evaluate the treatment patterns, clinical...
7.
Krishnakumar B, Christopher J, Prasobh P, Godbole S, Mehrotra A, Singhal A, et al.
J Family Med Prim Care
. 2022 Sep;
11(6):2589-2596.
PMID: 36119181
Objective: The aim of this study was to understand the prevalence, extent, clinical approach of hypertension and cardiovascular disease (CVD) in patients recovered from COVID-19. Methods: The round table meetings...
8.
Ram C, Mohan V, Pandit K, Kumar S, Sahay R, John M, et al.
J Assoc Physicians India
. 2022 Jul;
70(7):11-12.
PMID: 35833397
Objectives: This study evaluated the perception and practices of health care providers (physicians, diabetologists, and endocrinologists) regarding the treatment of hypertension in patients with diabetes in India. Methods: Health care...
9.
Jc M, Chopra A, Js H, Mahajan A, Nair T, Ray S, et al.
J Assoc Physicians India
. 2022 Apr;
70(3):11-12.
PMID: 35438293
Aim: To address the existing gaps in knowledge about long-acting nitroglycerine (LA-NTG) and provide recommendations to address these issues. Methodology: Approved LA-NTG questionnaire that included 17 questions related to the...
10.
Prem Kumar A, Ghorai A, Kriplani V, Dash R, Aravinda J, Shamanna P, et al.
Bioinformation
. 2022 Feb;
17(6):652-659.
PMID: 35173388
It is of interest to evaluate the clinical characteristics, treatment patterns, clinical effectiveness, and safety of telmisartan as a monotherapy or as part of combination therapy in Indian adults (>18...